Research programme: cancer therapeutics and diagnostic agents - Siamab Therapeutics

Drug Profile

Research programme: cancer therapeutics and diagnostic agents - Siamab Therapeutics

Alternative Names: Anti-glycan antibodies; Anti-Neu5Gc antibodies - Sialix; Anti-Sialyl-Tn antibodies; Anti-Sialyl-Tn monoclonal antibodies; Anti-STn antibodies; Humanised anti-Sialyl-Tn anti-CD3 bispecific antibodies; SIA01-ADC; SIA02-ADC; ST1 antibody drug conjugate programme

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sialix
  • Developer Massachusetts General Hospital; Siamab Therapeutics
  • Class Antineoplastics; Bispecific antibodies; Drug conjugates; Monoclonal antibodies
  • Mechanism of Action Polysaccharide inhibitors; Sialosyl Tn antigen inhibitors; Tumour-associated carbohydrate antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Colorectal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
  • Research Cancer

Most Recent Events

  • 30 Oct 2017 Pharmacodynamics and adverse events data from preclinical studies in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
  • 26 Oct 2017 Pharmacodynamics, pharmacokinetics and adverse events data from preclinical studies in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
  • 04 Oct 2017 Simab and Boehringer Ingelheim enter into a collaboration agreement to develop anti-cancer therapeutics targeting tumours associated carbohydrate antigens
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top